杂交瘤技术和单克隆抗体的专利问题

下载PDF

导出

作者谢建平

机构地区上海市恒泰(力保)律师事务所知识产权部

出处《中国生物工程杂志》 CAS CSCD 2003年第1期89-91,共3页 China Biotechnology

关键词杂交瘤技术单克隆抗体专利问题争议

参考文献10

1[1]The Wistar Institute. Method of producing antibodies. 1980,US Patent No. 4,196,265
2[2]The Wistar Institute. Method of producing tumor antibodies.1979, US Patent No. 4,172,124
3[3]Crawley, P E. Antibody Patents. In Monoclonal Antibodies:Principles and Applications Birch J R, Lennox E S, eds),Wiley-Liss Inc. 1995, pp. 299～335
4[4]Hodgson J. Patent case unblocks antibody businesses. Nature Biotechnol. 1999, 17,1154～1155
5[5]Ansell P R J. Hybridoma technology: a view from the patent arena. Trends immunology, 2000,21(8) :357～358
6[6]Ekins R A. Shadow over immunoassay. Nature, 1989,340, 256～258
7[7]Green H E, Duft B J. Disputes over monoclonal antibodies.Nature, 1990,347, 117～118
8[8]Marshall E. Biotech Giants Butt Heads Over Cancer Drug.Science, 2000, 288,2303
9[9]Tansey E M, Catterall P P. Technology transfer in Britain: the case of monoclonal antibodies. Contemp Rec, 1995,9, 409～444
10[10]Barton J H. Changing intellectual property issues in the biotechnology industry. Biotechnology Law Rep, 1999,18, 3～13

中国生物工程杂志

2003年第1期

内容加载中请稍等...